The best ideas happen when the right people work together.
At Curebound, collaboration is everything.
Our funding model engineers collaboration across multiple disciplines and institutions. We provide early phase, follow-on and clinical trial funding to cross-institutional research teams that bring together physician scientists, clinical researchers, and basic-science researchers to work in partnership on a specific challenge in cancer research.
This combination of bringing clinical data to early, basic discovery research is unique to Curebound, and creates collaborations that otherwise would not exist.
Curebound considers applications for all types of cancer research projects and can curate opportunities for individuals to invest in specific areas of research. For philanthropists and organizations looking to direct funding toward exploration of a particular cancer type or treatment area, Curebound’s world class Scientific Advisory Board (SAB) will make discerning investments.
Curebound funds three types of cancer research grants:
• First time seed grants for high-risk, high-reward, collaborative, translational research. Ideas are innovative and in the early phases, where smaller grants of $250,000 can make a big impact in advancing research
• Discovery Grants are one-time grants and will be determined by the peer-review process established by Padres Pedal the Cause and implemented by the six beneficiary institutions.
• Larger gift of $500,000 for 1-year with the option to re-apply for additional funding in subsequent years, that provide follow on funding to projects that continue the investigators previous line of research.
• The SAB will also consider targeted funding for major public health and population studies as they align with Curebound investment pillars.
• Innovative, game changing, multidisciplinary projects that receive major funding of $1,000,000, administered over multiple years.
• Cure Prize concepts will be determined collectively by the SAB and will seek to foster collaborations with and invoke matching funds from corporate industry partners, private investors, major federal grants and grants from other foundations.
2022 Curebound Cure Prize Challenge is closed as of August 15th 2022.
Curebound raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application. The full index of our research portfolio is available below.
Medulloblastoma is the most common malignant childhood brain tumor. It is a highly heterogeneous cancer, comprising four subgroups: Sonic Hedgehog, Wingless, Group 3, and Group 4. Group 3 MB has the worst prognosis of all Medulloblastomas. Group 3 often exhibits amplification of chromosome 8q24, which contains the potent oncogene MYC.Read More
Neuroblastoma is a tumor of developmental origin with high incidence of metastatic disease at initial diagnosis. Comprehensive DNA sequencing of high-risk neuroblastoma has identified few clinically actionable gene mutations and precision medicine has not benefited most neuroblastoma patients.Read More
Myelodysplastic syndrome (MDS) is a pre-cancer condition involving mutations in the stem cells which give rise to the many cell types which compose blood. These mutations cause stem cells to produce red blood cells and other cell types less efficiently, conditions called cytopenias — complications to which most MDS patients succumb.Read More
One approach to treating tumors uses intravenous therapies that help the immune system. This works in many cancers, however, this approach does not always work, and can fail with time as tumors find ways to avoid the immune system – even shutting off its ability to attack tumors.Read More
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 11%. Most patients die within 6 months of diagnosis from metastatic disease, but even patients who qualify for surgical resection eventually succumb to the disease. No targeted therapies are available.Read More
Brain and other tumors of the central-nervous system (CNS) are the most common cancers in children aged 0- 14 years in the USA. Ependymoma (EPN) is the third most common pediatric brain tumor and a leading cause of death in childhood cancer patients.Read More
Neuroblastoma is a cancer that accounts for more than 15% of all childhood cancer deaths. Despite multimodal therapy, the 5-year survival rate of children with high-risk disease is very low. Hence, novel, and safe therapies are needed to combat this childhood cancer. Here, we propose a targeted strategy to improve the effectiveness of anti-cancer therapy for this childhood cancer.Read More
Hundreds of thousands of years ago, before humans evolved from primates, another pandemic caused by viruses occurred. This pandemic was caused by retroviruses, which are viruses that can insert their own genetic information into the DNA of their hosts.Read More
One in six men will be diagnosed with prostate cancer (PCa), making it one of the leading health problems affecting men in today’s society. Patients diagnosed during the earlier stages are surviving longer due to improved therapies and the prevalence of prostate-specific antigen (PSA) testing.Read More